Equities

Nyrada Inc

NYR:ASX

Nyrada Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.057
  • Today's Change0.00 / 0.00%
  • Shares traded54.38k
  • 1 Year change+128.00%
  • Beta1.5645
Data delayed at least 20 minutes, as of Sep 19 2024 03:33 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Nyrada Inc grew revenues 115.55% from 1.58m to 3.40m while net income improved from a loss of 7.78m to a smaller loss of 1.39m.
Gross margin--
Net profit margin-40.89%
Operating margin-40.89%
Return on assets-25.13%
Return on equity-29.89%
Return on investment-29.75%
More ▼

Cash flow in AUDView more

In 2024, Nyrada Inc increased its cash reserves by 28.60%, or 1.06m. Cash Flow from Financing totalled 1.83m or 53.67% of revenues. In addition the company used 766.30k for operations while cash from investing was breakeven.
Cash flow per share-0.0085
Price/Cash flow per share--
Book value per share0.0277
Tangible book value per share0.0276
More ▼

Balance sheet in AUDView more

Nyrada Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.03
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.